Pembrolizumab in combination with chemotherapy has become the standard of care for patients diagnosed with non-small-cell lung cancer (NSCLC) with the expression of programmed death ligand 1 (PD-L1) in less than 50% tumour cells (TC). The gene discussed is CD274; the disease is non-small cell lung carcinoma.